{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:48:59Z","timestamp":1771667339007,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,2]]},"DOI":"10.7759\/cureus.23767","type":"journal-article","created":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T22:20:37Z","timestamp":1648938037000},"source":"Crossref","is-referenced-by-count":2,"title":["Solitary Primary Intracranial Extramedullary Plasmacytoma With Lymph Node Metastasis"],"prefix":"10.7759","author":[{"given":"Anna-Lena","family":"Meinhardt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher W","family":"Sandifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Dave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07421.x","article-title":"Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004","volume":"144","author":"Dores GM","year":"2009","unstructured":"Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol. 2009, 144:86-94. 10.1111\/j.1365-2141.2008.07421.x","journal-title":"Br J Haematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.4.255","article-title":"Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone","volume":"1","author":"Knowling MA","year":"1983","unstructured":"Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol. 1983, 1:255-62. 10.1200\/JCO.1983.1.4.255","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.248518","article-title":"Multiple myeloma with central nervous system relapse","volume":"105","author":"Egan PA","year":"2020","unstructured":"Egan PA, Elder PT, Deighan WI, O'Connor SJ, Alexander HD. Multiple myeloma with central nervous system relapse. Haematologica. 2020, 105:1780-90. 10.3324\/haematol.2020.248518","journal-title":"Haematologica"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04834.x","article-title":"Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma","volume":"124","author":"Soutar R","year":"2004","unstructured":"Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004, 124:717-26. 10.1111\/j.1365-2141.2004.04834.x","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-3015-5","article-title":"Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA","volume":"17","author":"Thumallapally N","year":"2017","unstructured":"Thumallapally N, Meshref A, Mousa M, Terjanian T. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer. 2017, 17:10.1186\/s12885-016-3015-5","journal-title":"BMC Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0099-8","article-title":"Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset","volume":"32","author":"Goyal G","year":"2018","unstructured":"Goyal G, Bartley AC, Funni S, et al.. Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. Leukemia. 2018, 32:1414-20. 10.1038\/s41375-018-0099-8","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4103\/1793-5482.143460","article-title":"Solitary dural plasmacytoma with parenchymal invasion","volume":"10","author":"Khalili RP","year":"2015","unstructured":"Khalili RP, Mokhtari M, Fard SA, Neshat A, Norouzi R. Solitary dural plasmacytoma with parenchymal invasion. Asian J Neurosurg. 2015, 10:102-4. 10.4103\/1793-5482.143460","journal-title":"Asian J Neurosurg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3171\/2008.2.17652","article-title":"Multiple myeloma manifesting as an intraventricular brain tumor","volume":"110","author":"Eum JH","year":"2009","unstructured":"Eum JH, Jeibmann A, Wiesmann W, Paulus W, Ebel H. Multiple myeloma manifesting as an intraventricular brain tumor. J Neurosurg. 2009, 110:737-9. 10.3171\/2008.2.17652","journal-title":"J Neurosurg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05199.x","article-title":"Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions","volume":"127","author":"Chang H","year":"2004","unstructured":"Chang H, Sloan S, Li D, Stewart AK. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004, 127:280-4. 10.1111\/j.1365-2141.2004.05199.x","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100672","article-title":"Dural plasmacytoma as the initial presentation of multiple myeloma: a case report and review of the literature","volume":"45","author":"Guo Y","year":"2021","unstructured":"Guo Y, Wei Y, Teng L, Lan X, Zhao H, Sun W. Dural plasmacytoma as the initial presentation of multiple myeloma: a case report and review of the literature. Curr Probl Cancer. 2021, 45:10.1016\/j.currproblcancer.2020.100672","journal-title":"Curr Probl Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2011.03793.x","article-title":"Expression of CD19 and lack of miR-223 distinguish extramedullary plasmacytoma from multiple myeloma","volume":"58","author":"Yu SC","year":"2011","unstructured":"Yu SC, Chen SU, Lu W, Liu TY, Lin CW. Expression of CD19 and lack of miR-223 distinguish extramedullary plasmacytoma from multiple myeloma. Histopathology. 2011, 58:896-905. 10.1111\/j.1365-2559.2011.03793.x","journal-title":"Histopathology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0549-1","article-title":"Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel","volume":"11","author":"Caers J","year":"2018","unstructured":"Caers J, Paiva B, Zamagni E, et al.. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018, 11:10.1186\/s13045-017-0549-1","journal-title":"J Hematol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00419-1","article-title":"Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up","volume":"11","author":"Manasanch EE","year":"2021","unstructured":"Manasanch EE, Kunacheewa C, Claussen CM, et al.. Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J. 2021, 11:10.1038\/s41408-021-00419-1","journal-title":"Blood Cancer J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2484-y","article-title":"Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience","volume":"94","author":"Katodritou E","year":"2015","unstructured":"Katodritou E, Terpos E, Kastritis E, et al.. Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. Ann Hematol. 2015, 94:2033-42. 10.1007\/s00277-015-2484-y","journal-title":"Ann Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1605067","article-title":"New insights in the treatment of patients with solitary bone plasmacytoma","volume":"60","author":"Mheidly K","year":"2019","unstructured":"Mheidly K, Chapelle TL, Hunault M, et al.. New insights in the treatment of patients with solitary bone plasmacytoma. Leuk Lymphoma. 2019, 60:2810-3. 10.1080\/10428194.2019.1605067","journal-title":"Leuk Lymphoma"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees PM","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, et al.. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020, 136:936-45. 10.1182\/blood.2020005288","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00404.x","article-title":"Autologous stem cell transplantation in patients with high-risk plasmacytoma","volume":"74","author":"Jantunen E","year":"2005","unstructured":"Jantunen E, Koivunen E, Putkonen M, Siitonen T, Juvonen E, Nousiainen T. Autologous stem cell transplantation in patients with high-risk plasmacytoma. Eur J Haematol. 2005, 74:402-6. 10.1111\/j.1600-0609.2004.00404.x","journal-title":"Eur J Haematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137237","article-title":"Superiority of thiotepa-containing conditioning regimens in patients with primary diffuse large b-cell lymphoma (DLBCL) of the central nervous system (CNS) undergoing autologous hematopoietic cell transplantation (autoHCT)","volume":"136","author":"Wang T","year":"2020","unstructured":"Wang T, Scordo M, Ahn KW, et al.. Superiority of thiotepa-containing conditioning regimens in patients with primary diffuse large b-cell lymphoma (DLBCL) of the central nervous system (CNS) undergoing autologous hematopoietic cell transplantation (autoHCT). Blood. 2020, 136:8-9. 10.1182\/blood-2020-137237","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.06.011","article-title":"High-dose melphalan plus thiotepa as conditioning regimen before second autologous stem cell transplantation for \"de\u00a0novo\" multiple myeloma patients: a phase II study","volume":"21","author":"Musso M","year":"2015","unstructured":"Musso M, Messina G, Marcacci G, et al.. High-dose melphalan plus thiotepa as conditioning regimen before second autologous stem cell transplantation for \"de\u00a0novo\" multiple myeloma patients: a phase II study. Biol Blood Marrow Transplant. 2015, 21:1932-8. 10.1016\/j.bbmt.2015.06.011","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/85590-solitary-primary-intracranial-extramedullary-plasmacytoma-with-lymph-node-metastasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:44:29Z","timestamp":1707507869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/85590-solitary-primary-intracranial-extramedullary-plasmacytoma-with-lymph-node-metastasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,2]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.23767","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,2]]}}}